PURPOSE Breast cancer is the most common cancer in women in India, with higher
incidence rates of aggressive subtypes, such as triple-negative breast cancer (TNBC) …

In the last two decades, India has witnessed a substantial increase in the incidence of breast
cancer and associated mortality. Studies on the prevalence of molecular subtypes of breast …

Background Androgen receptor (AR) is considered a marker of better prognosis in hormone
receptor positive breast cancers (BC), however, its role in triple negative breast cancer …

Background: There is growing evidence that the response to chemotherapy may be affected
by Androgen Receptor (AR) expression suggesting that triple-negative breast cancers …

We studied androgen receptor (AR) gene expression in primary breast cancer (BC) to
determine associations with clinical characteristics and outcomes in the I-SPY 1 study. AR …

Abstract Background The Androgen Receptor (AR) has emerged as an endocrine therapy
target in Breast Cancer, exhibiting up to 80% expression in clinical cases. AR-V7, a …

(1) Background: Neoadjuvant therapy is the main therapeutic strategy for human epidermal
growth factor receptor 2 (HER2)-positive breast cancer patients, and the combination of …

Purpose Women with breast tumors with higher expression of AR are in general known to
have better survival outcomes while a high AR/ER ratio is associated with poor outcomes in …

Background: The androgen receptor (AR) has recently emerged as a useful marker for the
more favorable prognosis and better outcomes among women with estrogen receptor (ER)+ …

Objective Cysteine conjugate beta-lyase 2 (CCBL2), also known as kynurenine
aminotransferase 3 (KAT3) or glutamine transaminase L (GTL), plays an essential role in …